article
Refining and targeting exatecan with ADC technology
DTR speaks with Dr Patrick van Berkel at ADC Therapeutics to discuss how the company is transforming exatecan delivery to achieve better health outcomes.
List view / Grid view
Ovarian cancer
news
FDA greenlights AI-developed drug targeting solid tumors
Insilico Medicine’s AI-designed drug ISM5939 has received FDA IND clearance for treating solid tumours. By targeting ENPP1, it enhances anti-tumour immunity and is set to begin Phase I trials soon.
news
Developing the world’s first ovarian cancer prevention vaccine
Cancer Research UK-funded researchers aim to identify targets for an ovarian cancer vaccine, which could prevent the disease at an early stage.
news
RAD51C variants linked to increased breast and ovarian cancer risk
Researchers have identified over 3,000 harmful genetic changes that could disrupt normal RAD51C function.
news
The mechanism of PARP inhibitor action is identified
New findings will enable the development of safer PARP inhibitors that inhibit PARP’s enzymatic activity without trapping it on DNA.
article
A new genetic biomarker to predict immunotherapy success
Tumours with a greater IGR burden could respond better to immune checkpoint blockades, advancing precise treatments for patients.
article
The potential of CD24 in cancer immunotherapy
Cofounder & Chief Scientific Officer of Pheast Therapeutics, Dr Roy Maute, reveals his company’s promising drug candidate and explains why they have focused on their chosen target.
news
New technique to extract and analyse extracellular vesicles
Cellulose nanofiber sheets enable analysis of EVs, and miRNAs within them, offering potential for cancer treatment and personalised medicine.
news
Synthetic proteins key to modular nanoparticle design
Researchers have been able to customise nanoparticles to target biological entities, like tumours and viruses.
news
New molecule disrupts pathways that promote cancer growth
Researchers have discovered a molecule that binds to a cancer cell protein, stopping growth of breast and ovarian tumours.
article
Condensate biology: advancing drug discovery for complex diseases
In this interview with Drug Target Review’s Izzy Wood and Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, discuss the innovative potential of condensate biology in revolutionising drug discovery. By targeting disease-driving condensates, Dewpoint’s research pushes boundaries by offering new hope for tackling diseases like ALS and colorectal cancer.
news
Unidentified proteins provide new way to diagnose ovarian cancer
Japanese study has identified three previously unknown membrane proteins in ovarian cancer, using a new detection method consisting of nanotechnology and imaging techniques.
article
New insight into BRCA2 gene mutations and cancer risk
A recent study from researchers at the University of California examines the BRCA2 gene, which plays a crucial role in repairing damaged DNA, and possible links with increased risk of breast and ovarian cancer.
article
Ovarian cancer breakthrough: the potential of rhenium tricarbonyl (TRIP) as a promising anti-tumour drug
In this exclusive article, Drug Target Review’s Izzy Wood highlights ground-breaking ovarian cancer research, after speaking with Dr Benjamin Neuditschko, from the Institute Krems Bioanalytics at IMC Krems.
news
New immunotherapy approach holds promise for ovarian cancer
A new approach using CAR T-cell therapy is suggested by Swedish researchers as an effective treatment for ovarian cancer.
